Progress in aptamer-mediated drug delivery vehicles for cancer targeting and its implications in addressing chemotherapeutic challenges.
Progress in aptamer-mediated drug delivery vehicles for cancer targeting and its implications in addressing chemotherapeutic challenges.
复制标题
作者：
Zhu J;Huang H;Dong S;Ge L;Zhang Y
适体是一种新型的寡核苷酸，具有灵活的三维构型，以高亲和力和高度特异性的方式识别并结合其同源靶标，包括肿瘤表面受体。由于其独特的内在性质，已经开发了各种适体介导的纳米载体，以将抗癌药物定向运输到肿瘤部位，以最小化全身细胞毒性并增强这些杀肿瘤剂的渗透。尽管在适体的选择和合成以及纳米技术的缀合和自组装方面取得了进展，但目前的化疗和药物递送系统面临着巨大的挑战。这些挑战是由于适体和载体的限制以及复杂的肿瘤机制，包括异质性，抗癌药物耐药性和缺氧诱导的异常。在这篇综述中，我们将总结目前的方法，利用肿瘤表面标志物和适体及其作用和机制的治疗纳米车辆靶向肿瘤。递送形式包括纳米颗粒、纳米管、纳米凝胶、适体-药物缀合物和新型分子链。此外，还将强调上述问题造成的障碍，并确认可能的解决办法。此外，还将介绍未来的前景，包括与RNA干扰纳米技术和个性化化疗的前沿整合，这将促进基于适体的治疗方法的创新。
Aptamers are novel oligonucleotides with flexible three-dimensional configurations that recognize and bind to their cognate targets, including tumor surface receptors, in a high-affinity and highly specific manner. Because of their unique intrinsic properties, a variety of aptamer-mediated nanovehicles have been developed to directionally transport anti-cancer drugs to tumor sites to minimize systemic cytotoxicity and to enhance permeation by these tumoricidal agents. Despite advances in the selection and synthesis of aptamers and in the conjugation and self-assembly of nanotechnologies, current chemotherapy and drug delivery systems face great challenges. These challenges are due to the limitations of aptamers and vehicles and because of complicated tumor mechanisms, including heterogeneity, anti-cancer drug resistance, and hypoxia-induced aberrances. In this review, we will summarize current approaches utilizing tumor surface hallmarks and aptamers and their roles and mechanisms in therapeutic nanovehicles targeting tumors. Delivery forms include nanoparticles, nanotubes, nanogels, aptamer-drug conjugates, and novel molecular trains. Moreover, the obstacles posed by the aforementioned issues will be highlighted, and possible solutions will be acknowledged. Furthermore, future perspectives will be presented, including cutting-edge integration with RNA interference nanotechnology and personalized chemotherapy, which will facilitate innovative approaches to aptamer-based therapeutics.
登录
查看更多内容
DOI：
10.1016/j.jconrel.2012.04.014
发表时间：
2012-12-10
期刊：
Journal of controlled release : official journal of the Controlled Release Society
影响因子：
--
作者：
Denison TA;Bae YH
通讯作者：
Bae YH
影响因子：
5.1
作者：
Chen, Wanqing;Zheng, Rongshou;He, Jie
通讯作者：
He, Jie
影响因子：
4.8
作者：
Chen, Yunching;Bathula, Surendar Reddy;Huang, Leaf
通讯作者：
Huang, Leaf
影响因子：
5.7
作者：
Girvan, Allicia C.;Teng, Yun;Bates, Paula J.
通讯作者：
Bates, Paula J.
影响因子：
46.9
作者：
Bhatia, Sangeeta;Frangioni, John V.;Polyak, Kornelia
通讯作者：
Polyak, Kornelia